Close Menu

Bruker Reports Strong Q3, Considerable TOF/TOF Sales to Academic Institutions

Having spilled some of its goodies already in an October presentation at an investors’ meeting (see ProteoMonitor, 10-21-02), Bruker Daltonics formally reported last week that its revenues were up 22 percent for the third quarter. These revenues totaled $29.7 million, compared to $23.8 million in the third quarter of 2001. The company’s net income totaled $1.7 million, up from $925,000 in the previous year’s third quarter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.